Anti-addiction vaccines

F1000 Medicine Reports

Volumn 3, Issue 1, 2011, Pages

  Shen, Xiaoyun ^a   Orson, Frank M ^a,b   Kosten, Thomas R ^a,b  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b MICHAEL E DEBAKEY VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMFEBUTAMONE; CHOLERA TOXIN; COCAINE VACCINE; DIAMORPHINE; DRUGS USED IN THE TREATMENT OF ADDICTION; METHADONE; METHAMPHETAMINE; METHAMPHETAMINE VACCINE; MORPHINE; NALTREXONE; NIC002; NICOTINE QBETA; NICOTINE VACCINE; OXYCODONE; PLACEBO; RECOMBINANT VACCINE; TA NIC; UNCLASSIFIED DRUG; VARENICLINE;

AGGRESSION; CLINICAL TRIAL (TOPIC); COCAINE DEPENDENCE; DRUG DEPENDENCE; EXCITABILITY; HUMAN; INFLUENZA; INSOMNIA; MULTICENTER STUDY (TOPIC); NARCOTIC DEPENDENCE; OPIATE ADDICTION; PANIC; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PSYCHOSIS; RESPIRATION DEPRESSION; REVIEW; SEIZURE; SIDE EFFECT; STROKE;

EID: 80053462751     PISSN: None     EISSN: 17575931     Source Type: Journal    
DOI: 10.3410/M3-20     Document Type: Review

References (75)

1. United Nations Office on Drugs and Crime: World Drug Report 2011. United Nations Publication, Sales No. E.11.XI.10. [http://www. unodc.org/documents/ data-and-analysis/WDR2011/World-Drug- Report-2011-ebook.pdf]
2. Fox BS, Kantak KM, Edwards MA, Black KM, Bollinger BK, Botka AJ, French TL, Thompson TL, Schad VC, Greenstein JL, Gefter ML, Exley MA, Swain PA, Briner TJ: Efficacy of a therapeutic cocaine vaccine in rodent models. Nat Med 1996, 2:1129-32. F1000 Factor 6 Evaluated by Thomas Kosten 20 Sep 2011
3. Pentel PR, Malin DH, Ennifar S, Hieda Y, Keyler DE, Lake JR, Milstein JR, Basham LE, Coy RT, Moon JW, Naso R, Fattom A: A nicotine conjugate vaccine reduces nicotine distribution to brain and attenuates its behavioral and cardiovascular effects in rats. Pharmacol Biochem Behav 2000, 65:191-8. F1000 Factor 6 Evaluated by Thomas Kosten 20 Sep 2011
4. Byrnes-Blake KA, Laurenzana EM, Carroll FI, Abraham P, Gentry WB, Landes RD, Owens SM: Pharmacodynamic mechanisms of monoclonal antibody-based antagonism of (+)-methamphetamine in rats. Eur J Pharmacol 2003, 14:119-28. F1000 Factor 6 Evaluated by Thomas Kosten 20 Sep 2011
5. Laurenzana EM, Byrnes-Blake KA, Milesi-Hallé A, Gentry WB, Williams DK, Owens SM: Use of anti-(+)-methamphetamine monoclonal antibody to significantly alter (+)-methamphetamine and (+)-amphetamine disposition in rats. Drug Metab Dispos 2003, 31:1320-6. F1000 Factor 6 Evaluated by Thomas Kosten 20 Sep 2011
6. Laurenzana EM, Hendrickson HP, Carpenter D, Peterson EC, Gentry WB, West M, Che Y, Carroll FI, Owens SM: Functional and biological determinants affecting the duration of action and efficacy of anti-(+)-methamphetamine monoclonal antibodies in rats. Vaccine 2009, 27:7011-20. F1000 Factor 6 Evaluated by Thomas Kosten 20 Sep 2011
7. Berkowitz B, Spector S: Evidence for active immunity to morphine in mice. Science 1972, 178:1290-2. F1000 Factor 8 Evaluated by Thomas Kosten 20 Sep 2011
8. Bonese KF, Wainer BH, Fitch FW, Rothberg RM, Schuster CR: Changes in heroin self-administration by a rhesus monkey after morphine immunisation. Nature 1974, 252:708-10. F1000 Factor 8 Evaluated by Thomas Kosten 20 Sep 2011
9. Kreek MJ, Borg L, Ducat E, Ray B: Pharmacotherapy in the treatment of addiction: methadone. J Addict Dis 2010, 29:200-16.
10. Minozzi S, Amato L, Vecchi S, Davoli M, Kirchmayer U, Verster A: Oral naltrexone maintenance treatment for opioid dependence. Cochrane Database Syst Rev 2011, 2:CD001333.
11. Maurer P, Bachmann MF: Vaccination against nicotine: an emerging therapy for tobacco dependence. Expert Opin Investig Drugs 2007, 16:1775-83. (Pubitemid 350187391)
12. Hatsukami DK, Jorenby DE, Gonzales D, Rigotti NA, Glover ED, Oncken CA, Tashkin DP, Reus VI, Akhavain RC, Fahim RE, Kessler PD, Niknian M, Kalnik MW, Rennard SI: Immunogenicity and smoking-cessation outcomes for a novel nicotine immunotherapeutic. Clin Pharmacol Ther 2011, 89:392-9. F1000 Factor 6 Evaluated by Thomas Kosten 20 Sep 2011
13. Haney M, Kosten TR: Therapeutic vaccines for substance dependence. Expert Rev Vaccines 2004, 3:11-8. (Pubitemid 38196951)
14. Orson FM, Kinsey BM, Singh RA, Wu Y, Gardner T, Kosten TR: Substance abuse vaccines. Ann N Y Acad Sci 2008, 1141:257-69.
15. Kosten TR, Biegel D: Therapeutic vaccines for substance dependence. Expert Rev Vaccines 2002, 1:363-71. (Pubitemid 36559871)
16. Substance Abuse and Mental Health Services Administration: Results from the 2005 National Survey on Drug Use and Health: National Findings. Office of Applied Studies, NSDUH Series H-30, DHHS Publication No. SMA 06-4194. Rockville, MD; 2006. [http://oas.samhsa.gov/nsduh/2k5nsduh/2k5Results.htm]
17. Karila L, Gorelick D, Weinstein A, Noble F, Benyamina A, Coscas S, Blecha L, Lowenstein W, Martinot JL, Reynaud M, Lépine JP: New treatments for cocaine dependence: a focused review. Int J Neuropsychopharmacol 2008, 11:425-38. F1000 Factor 6 Evaluated by Thomas Kosten 20 Sep 2011
18. Martell BA, Orson FM, Poling J, Mitchell E, Rossen RD, Gardner T, Kosten TR: Cocaine vaccine for the treatment of cocaine dependence in methadone-maintained patients: a randomized, double-blind, placebo-controlled efficacy trial. Arch Gen Psychiatry 2009, 66:1116-23. F1000 Factor 8 Evaluated by Harriet de Wit 31 Dec 2009
19. Martell BA, Mitchell E, Poling J, Gonsai K, Kosten TR: Vaccine pharmacotherapy for the treatment of cocaine dependence. Biol Psychiatry 2005, 58:158-64. (Pubitemid 41008133)
20. Haney M, Gunderson EW, Jiang H, Collins ED, Foltin RW: Cocainespecific antibodies blunt the subjective effects of smoked cocaine in humans. Biol Psychiatry 2010, 67:59-65. F1000 Factor 6 Evaluated by Thomas Kosten 20 Sep 2011
21. Stewart DJ, Inaba T, Lucassen M, Kalow W: Cocaine metabolism: cocaine and norcocaine hydrolysis by liver and serum esterases. Clin Pharmacol Ther 1979, 25:464-8. F1000 Factor 6 Evaluated by Thomas Kosten 20 Sep 2011
22. Williams RH, Maggiore JA, Shah SM, Erickson TB, Negrusz A: Cocaine and its major metabolites in plasma and urine samples from patients in an urban emergency medicine setting. J Anal Toxicol 2000, 24:478-81.
23. Esson L, SR Leeder: The millennium development goals and tobacco control: an opportunity for global partnership. Geneva: World Health Organization (WHO); 2004.
24. Tobacco Free Initiative (TFI): Why is tobacco a public health priority? World Health Organization (WHO); 2005. [http://www. who.int/tobacco/health- priority/en]
25. Aubin HJ, Karila L, Reynaud M: Pharmacotherapy for smoking cessation: present and future. Curr Pharm Des 2011, 17:1343-50.
26. Hays JT, Ebbert JO: Adverse effects and tolerability of medications for the treatment of tobacco use and dependence. Drugs 2010, 70:2357-72.
27. Centers for Disease Control and Prevention: 2004 Surgeon General's Report-The Health Consequences of Smoking. [http://www.cdc.gov/tobacco/data- statistics/sgr/2004/index.htm]
28. Hieda Y, Keyler DE, Ennifar S, Fattom A, Pentel PR: Vaccination against nicotine during continued nicotine administration in rats: immunogenicity of the vaccine and effects on nicotine distribution to brain. Int J Immunopharmacol 2000, 22:809-19. F1000 Factor 6 Evaluated by Thomas Kosten 20 Sep 2011
29. Polosa R, Benowitz NL: Treatment of nicotine addiction: present therapeutic options and pipeline developments. Trends Pharmacol Sci 2011, 32:281-9. F1000 Factor 6 Evaluated by Thomas Kosten 20 Sep 2011
30. Cornuz J, Zwahlen S, Jungi WF, Osterwalder J, Klingler K, van Melle G, Bangala Y, Guessous I, Müller P, Willers J, Maurer P, Bachmann MF, Cerny T: A vaccine against nicotine for smoking cessation: a randomized controlled trial. PLoS One 2008, 3: e2547. F1000 Factor 6 Evaluated by Thomas Kosten 20 Sep 2011
31. Cytos Biotechnology: CYT002 Nic Qb: a novel vaccine for nicotine addiction. Zurich: Cytos Biotechnology; 2006. [http://www.cytos.com/doc/NicQb- June06-E-fv.pdf]
32. Nabi Biopharmaceuticals: Clinical Trials: NicVAX® (Nicotine Conjugate Vaccine). [http://www.nabi.com/pipeline/clinicaltrials. php]
33. Nabi Biopharmaceuticals: News Release: Nabi Biopharmaceuticals Announces Results of First NicVAX(R) Phase III Clinical Trial. Smoking Cessation Immunotherapy Failed to Meet Primary Endpoint. [http://phx.corporate-ir.net/ phoenix.zhtml? c=100445&p=irol-newsArticle&ID=1586001&highlight=]
34. Darke S, Kaye S, McKetin R, Duflou J: Major physical and psychological harms of methamphetamine use. Drug Alcohol Rev 2008, 27:253-62.
35. Fowler JS, Volkow ND, Logan J, Alexoff D, Telang F, Wang GJ, Wong C, Ma Y, Kriplani A, Pradhan K, Schlyer D, Jayne M, Hubbard B, Carter P, Warner D, King P, Shea C, Xu Y, Muench L, Apelskog K: Fast uptake and long-lasting binding of methamphetamine in the human brain: comparison with cocaine. Neuroimage 2008, 43:756-63. F1000 Factor 6 Evaluated by Thomas Kosten 20 Sep 2011
36. Cook CE, Jeffcoat AR, Hill JM: Pharmacokinetics of methamphetamine self-administered to human subjects by smoking S- (1) -methamphetamine hydrochloride. Drug Metab Dispos 1993, 21:717-23. (Pubitemid 23221770)
37. Volkow ND, Fowler JS, Wang GJ, Shumay E, Telang F, Thanos PK, Alexoff D: Distribution and pharmacokinetics of methamphetamine in the human body: clinical implications. PLoS One 2010, 5:e15269. F1000 Factor 6 Evaluated by Thomas Kosten 20 Sep 2011
38. Fowler JS, Kroll C, Ferrieri R, Alexoff D, Logan J, Dewey SL, Schiffer W, SchlyerD,CarterP, KingP, SheaC,XuY,MuenchL,BenvenisteH, VaskaP, Volkow ND: PET studies of d-methamphetamine pharmacokinetics in primates: comparison with l-methamphetamine and (-)-cocaine. J Nucl Med 2007, 48:1724-32. F1000 Factor 6 Evaluated by Thomas Kosten 20 Sep 2011
39. Karch SB: Karch's Pathology of Drug Abuse - Fourth Edition. Boca Raton, FL: CRC Press; 2008.
40. Quinn DI, Wodak A, Day RO: Pharmacokinetic and pharmacodynamic principles of illicit drug use and treatment of illicit drug users. Clin Pharmacokinet 1997, 33:344-400. (Pubitemid 27480938)
41. Gonzales R, Mooney L, Rawson RA: The methamphetamine problem in the United States. Annu Rev Public Health 2010, 31:385-98. F1000 Factor 6 Evaluated by Thomas Kosten 20 Sep 2011
42. McKetin R, Kozel N, Douglas J, Ali R, Vicknasingam B, Lund J, Li JH: The rise of methamphetamine in Southeast and East Asia. Drug Alcohol Rev 2008, 27:220-8. F1000 Factor 6 Evaluated by Thomas Kosten 20 Sep 2011
43. Meijler MM, Matsushita M, Wirsching P, Janda KD: Development of immunopharmacotherapy against drugs of abuse. Curr Drug Discov Technol 2004, 1:77-89. F1000 Factor 6 Evaluated by Thomas Kosten 20 Sep 2011
44. Substance Abuse and Mental Health Services Administration: Results from the 2008 National Survey on Drug Use and Health: National Findings. Office of Applied Studies, NSDUH Series H-36, HHS Publication No. SMA 09-4434. Rockville, MD; 2009. [http://oas.samhsa.gov/nsduh/2k8nsduh/2k8Results.cfm]
45. US Department of Justice, National Drug Intelligence Center: National Drug Threat Assessment 2003. Johnstown, PA: National Drug Intelligence Center; 2003. [http://www.justice.gov/ndic/pubs3/3300/ index.htm]
46. Byrnes-Blake KA, Carroll FI, Abraham P, Owens SM: Generation of anti-(+)methamphetamine antibodies is not impeded by (+) methamphetamine administration during active immunization of rats. Int Immunopharmacol 2001, 1:329-38. F1000 Factor 6 Evaluated by Thomas Kosten 20 Sep 2011
47. Moreno AY, Mayorov AV, Janda KD: Impact of distinct chemical structures for the development of a methamphetamine vaccine. J Am Chem Soc 2011, 133:6587-95. F1000 Factor 6 Evaluated by Thomas Kosten 20 Sep 2011
48. Peterson EC, Gunnell M, Che Y, Goforth RL, Carroll FI, Henry R, Liu H, Owens SM: Using hapten design to discover therapeutic monoclonal antibodies for treating methamphetamine abuse. J Pharmacol Exp Ther 2007, 322:30-9. F1000 Factor 6 Evaluated by Thomas Kosten 20 Sep 2011
49. Owens SM, Mayersohn M: Phencyclidine-specific Fab fragments alter phencyclidine disposition in dogs. Drug Metab Dispos 1986, 14:52-8. (Pubitemid 16152314)
50. McMillan DE, HardwickWC, Li M, Gunnell MG, Carroll FI, Abraham P, Owens SM: Effects of murine-derived anti-methamphetamine monoclonal antibodies on (+)-methamphetamine selfadministration in the rat. J Pharmacol Exp Ther 2004, 309:1248-55. (Pubitemid 38669716)
51. Byrnes-Blake KA, Laurenzana EM, Landes RD, Gentry WB, Owens SM: Monoclonal IgG affinity and treatment time alters antagonism of (+)-methamphetamine effects in rats. Eur J Pharmacol 2005, 521:86-94. (Pubitemid 41427794)
52. Gentry WB, Laurenzana EM, Williams DK, West JR, Berg RJ, Terlea T, Owens SM: Safety and efficiency of an anti-(+)- methamphetamine monoclonal antibody in the protection against cardiovascular and central nervous system effects of (+)-methamphetamine in rats. Int Immunopharmacol 2006, 6:968-77.
53. Coffman RL, Sher A, Seder RA: Vaccine adjuvants: putting innate immunity to work. Immunity 2010, 33:492-503.
54. Leshner AI: Comments on "The moral economies of homeless heroin addicts: confronting ethnography, HIV risk, andeveryday violence in San Francisco shooting encampments". by Phillippe Bourgois. Subst Use Misuse 1998, 33:2369-74. F1000 Factor 6 Evaluated by Thomas Kosten 20 Sep 2011
55. Tang YL, Zhao D, Zhao C, Cubells JF: Opiate addiction in China: current situation and treatments. Addiction 2006, 101:657-65. F1000 Factor 6 Evaluated by Thomas Kosten 20 Sep 2011
56. Substance Abuse and Mental Health Services Administration: Results from the 2007 National Survey on Drug Use and Health: National Findings. Office of Applied Studies, NSDUH Series H-34, DHHS Publication No. SMA 08-4343. Rockville, MD; 2008. [http://oas.samhsa.gov/nsduh/2k7nsduh/2k7Results.cfm]
57. Dekimpe MG, van de Gucht LM, Hanssens DM, Powers KI: Long run abstinence after narcotics abuse: What are the odds? Manag Sci 1998, 44:1478-92. F1000 Factor 6 Evaluated by Thomas Kosten 20 Sep 2011
58. Gossop M, Stewart D, Browne N, Marsden J: Factors associated with abstinence, lapse or relapse to heroin use after residential treatment: protective effect of coping responses. Addiction 2002, 97:1259-67. F1000 Factor 6 Evaluated by Thomas Kosten 20 Sep 2011
59. Maxwell S, Shinderman MS: Optimizing long-term response to methadone maintenance treatment: a 152-week follow-up using higher-dose methadone. J Addict Dis 2002, 21:1-12. F1000 Factor 6 Evaluated by Thomas Kosten 20 Sep 2011
60. Mark TL, Woody GE, Juday T, Kleber HD: The economic costs of heroin addiction in the United States. Drug Alcohol Depend 2001, 61:195-206. F1000 Factor 6 Evaluated by Thomas Kosten 20 Sep 2011
61. van Vunakis H, Wasserman E, Levine L: Specificities of antibodies to morphine. J Pharmacol Exp Ther 1972, 180:514-21. F1000 Factor 6 Evaluated by Thomas Kosten 20 Sep 2011
62. Wainer BH, Fitch FW, Fried J, Rothberg RM: A measurement of the specificities of antibodies to morphine-6-succinyl-BSA by competitive inhibition of 14 C-morphine binding. J Immunol 1973, 110:667-73. F1000 Factor 6 Evaluated by Thomas Kosten 20 Sep 2011
63. Koida M, Takahashi M, Muraoka S, Kaneto H: Antibodies to BSA conjugates of morphine derivatives: strict dependency of the immunological specificity on the hapten structure. Jpn J Pharmacol 1974, 24:165-7. F1000 Factor 6 Evaluated by Thomas Kosten 20 Sep 2011
64. Akbarzadeh A, Mehraby M, Zarbakhsh M, Farzaneh H: Design and synthesis of a morphine-6-succinyl-bovine serum albumin hapten for vaccine development. Biotechnol Appl Biochem 1999, 30:139-46. F1000 Factor 6 Evaluated by Thomas Kosten 20 Sep 2011
65. Anton B, Leff P: A novel bivalent morphine/heroin vaccine that prevents relapse to heroin addiction in rodents. Vaccine 2006, 24:3232-40. F1000 Factor 6 Evaluated by Thomas Kosten 20 Sep 2011
66. Ma LX, Zhou Q, Zheng HB, Li SB: Preparation and characterization of anti-morphine vaccine antibody. Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi 2006, 22:368-70. F1000 Factor 6 Evaluated by Thomas Kosten 20 Sep 2011
67. Stowe GN, Vendruscolo LF, Edwards S, Schlosburg JE, Misra KK, Schulteis G, Mayorov AV, Zakhari JS, Koob GF, Janda KD: A Vaccine Strategy that Induces Protective Immunity against Heroin. J Med Chem 2011, 54:5195-204. F1000 Factor 6 Evaluated by Thomas Kosten 20 Sep 2011
68. Shen X, Lopez A, Kinsey BM, Singh RA, Wu Y, Mao B, Orson FM: Morphine Vaccination and Inhibition of Morphine Induced Analgesia in Mice [abstract]. Presented at 13th World Vaccine Congress: March 2011; Beijing, China; 341.
69. Shen X, Kosten TA, Lopez AY, O'Malley PW, Wu Y, Kinsey BM, Orson FM: Morphine vaccination and its inhibition of morphine induced CPP and analgesia in rats [abstract]. Presented at 73rd Annual Meeting of the College on Problems of Drug Dependence: 18-23 June 2011; Hollywood, FL.
70. Inturrisi CE, Schultz M, Shin S, Umans JG, Angel L, Simon EJ: Evidence from opiate binding studies that heroin acts through its metabolites. Life Sci 1983, 33(Suppl 1):773-6. F1000 Factor 6 Evaluated by Thomas Kosten 20 Sep 2011
71. De Wit H: Priming effects with drugs and other reinforcers. Exp Clin Psychopharmacol 1996, 4:5-10. F1000 Factor 6 Evaluated by Thomas Kosten 20 Sep 2011
72. Hall W, Carter L: Ethical implications of using a cocaine vaccine to treat and prevent cocaine dependence. J Med Ethics 2004, 30:337-40. F1000 Factor 6 Evaluated by Thomas Kosten 20 Sep 2011
73. Hall W, Gartner C: Ethical and policy issues in using vaccines to treat and prevent cocaine and nicotine dependence. Curr Opin Psychiatry 2011, 24:191-6. F1000 Factor 6 Evaluated by Thomas Kosten 20 Sep 2011
74. Edited by Harwood HJ, Myers TG: National Research Council & Institute of Medicine: New Treatments for Addiction: Behavioral, Ethical, Legal, and Social Questions. Washington, DC: National Academies Press; 2004.
75. Spooner C, Hall W, Mattick RP: An overview of diversion strategies for Australian drug related offenders. Drug Alcohol Rev 2001, 20:281-94. F1000 Factor 6 Evaluated by Thomas Kosten 20 Sep 2011